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Candida auris is a recently emerged multidrug-resistant fungal pathogen causing severe
illness in hospitalized patients. C. auris is most closely related to a few environmental
or rarely observed but cosmopolitan Candida species. However, C. auris is unique in
the concern it is generating among public health agencies for its rapid emergence,
difficulty to treat, and the likelihood for further and more extensive outbreaks and spread.
To date, five geographically distributed and genetically divergent lineages have been
identified, none of which includes isolates that were collected prior to 1996. Indeed,
C. auris’ ecological niche(s) and emergence remain enigmatic, although a number of
hypotheses have been proposed. Recent genomic and transcriptomic work has also
identified a variety of gene and chromosomal features that may have conferred C. auris
with several important clinical phenotypes including its drug-resistance and growth at
high temperatures. In this review we discuss nine major lines of enquiry into C. auris that
big-data technologies and analytical approaches are beginning to answer.
Keywords: Candida auris, genomics, emergence, antifungal resistance mechanisms, virulence factors,
epigenetics
THE EVOLUTION OF C. auris AND CLOSEST RELATIVES
Candida auris was first isolated from the external ear canal (auris is Latin for “ear”) of an 70 years
old Japanese woman, who was a patient at Tokyo Metropolitan Geriatric Hospital (Tokyo, Japan)
in 2009 (Satoh et al., 2009). This first isolate (type strain JCM15448; CBS10913; DSM21092) had
several attributes that distinguished it from its closest known relatives, warranting its demarcation
as a new species. Unique features of C. auris included the ability to grow (albeit slow and with weak
growth) at 42◦C, while isolates from its three closest relatives (C. haemulonii, C. pseudohaemulonii,
or C. heveicola) were unable to grow at this temperature (Satoh et al., 2009). JCM15448 showed a
reduced ability to assimilate different carbon sources (galactose, l−sorbose, cellobiose, l−arabinose,
ethanol, glycerol, salicin, or citrate), whilst C. ruelliae was able to assimilate all of those as carbon
sources (although C. ruelliae is able to grow at 42◦C). JCM15448 produced no pseudohypae while
all closest relatives (C. haemulonii species complex. C. heveicola, and C. ruelliea) were able to. The
authors concluded that isolate JCM15448 belonged to a new species, and “may have pathogenicity,
but this will be elucidated in future studies” (Satoh et al., 2009).
C. auris falls within the Clavispora clade of the Metschnikowiaceae family of the order
Saccharomycetales, which are ascomycetous (hemiascomycetes) yeasts that reproduce by budding.
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GRAPHICAL ABSTRACT | An overview of the nine chapters of this review.
Saccharomycetales includes approximately 1000 described
species including human commensals and pathogens (e.g.,
C. albicans), plant pathogens (e.g., Eremothecium gossypii),
species important for baking and brewing (e.g., Saccharomyces
cerevisiae), species that have associations and interactions
with plants and/or arthropods, as well as numerous free
living saprobes. The most widely studied Candida species are
C. albicans, C. tropicalis, and C. parapsilosis from the CTG
clade – defined by predominantly translating the codon CTG
to serine instead of leucine (Santos et al., 2011). Genetically
distinct is C. glabrata, which falls in the Nakaseomyces clade
(Angoulvant et al., 2016) and is also of growing interest primarily
due to its increasing prevalence in nosocomial infections
(Toda et al., 2019). These four species together accounted for
approximately 90% of species responsible for invasive candidiasis
during 2003 (Pfaller and Diekema, 2007). Although C. auris is
genetically divergent from the other commonly studied CTG
clade species, it also translates the codon CTG to serine and
is within the CTG clade (Muñoz et al., 2018). C. auris’ genetic
distance from other more commonly studied species and its
recent emergence raises many questions regarding its evolution,
epidemiology, and the genetic basis for its pathogenicity and
drug resistance.
The phylogenetic relationship of C. auris to other known
species is still not fully resolved, mainly owing to the
rarity of some of its closest relatives. Maximum likelihood
phylogenetic reconstruction has revealed that four of the five
clades of C. auris (with genomic analyses of Clade V not
reported yet) are highly genetically related (98.7% average
pairwise nucleotide identity), all of which are more distantly
related to other Candida species that have their genome
sequenced including C. haemulonii, C. duobushaemulonii,
and C. psuedohaemulonii (88% average pairwise nucleotide
identity) (Muñoz et al., 2018). Given the recency of emergence
and discovery of already five clades within the C. auris
species, it seems likely that further clades await discovery.
Muñoz et al. found the most closely related species to be
C. haemulonii, followed by C. pseudohaemulonii – both of
which are occasionally found in animal or clinical settings
(Cendejas-Bueno et al., 2012).
Early non-whole-genome sequencing (specifically 26S rDNA
D1/D2 domain) suggested C. auris may be more closely
related to C. ruelliae than C. haemulonii (Satoh et al., 2009),
a species identified from the flowers of the Ruellia species of
the Acanthaceae family (Saluja and Prasad, 2008). C. ruelliae
has not been reported since to the best of our knowledge, and
has not had its genome sequenced, thereby hampering efforts to
phylogenetically place it, and verify its relationship to C. auris.
ITS and rDNA sequencing meanwhile suggest that C. auris
groups phylogenetically with C. heveicola (Satoh et al., 2009),
a species described by a single isolate YJ2E(T) identified from
tree sap from tropical forests in Yunnan and Hainan Provinces
in southern China (Wang et al., 2008). Similarly, C. heveicola
has also not been re-identified or had its full genome sequenced.
Evidently, much remains to be known about true genome
diversity of both C. auris and its closest relatives.
One of the closest known relatives of C. auris is C. haemulonii,
which was first discovered in 1962 (formerly named Torulopsis
haemulonii) from the gut of a blue-striped grunt fish (Haemulon
scirus) (van Uden and Kolipinski, 1962), which is found in the
Western Atlantic, Gulf of Mexico and the Caribbean. It was
also isolated from the skin of dolphins and seawater off the
coast of Portugal (van Uden and Kolipinski, 1962; Khan et al.,
2007). C. haemulonii has also been found from terrestrial sources
including the roots of Cassava (Manihot esculenta) in Brazil in
2010, and in a laboratory tick colony (Ornithodoros moubata) in
the Czech Republic in 2001 (Jackson et al., 2019). C. haemulonii
has also been the cause of candidemia and other bloodstream
infections, catheter-related fungemia, osteitis, and even outbreaks
in intensive care units (Cendejas-Bueno et al., 2012) including in
Kuwait in 2005 (Khan et al., 2007).
In 1993, Lehmann et al. (1993) found C. haemulonii to
comprise two separate groups (group I and II). In 2012, Cendejas-
Bueno et al. (2012) redefined group I as the C. haemulonii
species, and re-categorized group II as the new species
C. duobushaemulonii based on genetic differences, ability
to grow at different temperatures and on different carbon
sources, and drug susceptibilities. C. duobushaemulonii has
been isolated from patients’ blood and foot ulcers in Asia,
Europe, and North America, and has been the cause of
recurrent vulvovaginal candidiasis (VVC) in Brazil (Jackson
et al., 2019). C. duobushaemulonii has also been isolated from
a firebug (Pyrrhocoris apterus) in Germany (Jackson et al.,
2019). In 2006, Sugita et al. (2006) described a closely related
but distinct species to C. haemulonii, C. pseudohaemulonii,
which was isolated from the blood of a Thai patient. Recent
genome sequencing showed 92% nucleotide genome identity
between C. pseudohaemulonii and C. duobushaemulonii and
several chromosomal rearrangements confirming their genetic
divergence (Muñoz et al., 2018).
The evolution and phylogenetics of C. auris remain enigmatic,
due to the disparate ecological sources of its closest relatives,
their genetic distance, and that most have not yet had their
genomes sequenced and compared, thus precluding detailed
population genetic analysis within these species. The discovery of
more closely related species by concerted sampling efforts, along
with genome sequencing of others already identified but without
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reference genomes such as C. ruelliae or C. heveicola may provide
additional clues about their and C. auris’ evolution.
THE GENOME OF C. auris
To date, five genetically diverse clades have been discovered. The
first genome assemblies came from isolates belonging to Clade I,
such as the Illumina-based genome of isolate Ci6684 (Chatterjee
et al., 2015), and Illumina and Nanopore based genomes of
five isolates from an outbreak in London, United Kingdom
(Rhodes et al., 2018b). Shortly after, Muñoz et al. (2018)
assembled and compared genomes across four (Clade I- > IV)
of the then known lineages. Muñoz mapped the genomes into
seven chromosomes using optical maps, and recent work using
long-reads and telomere-to-telomere assemblies confirm the
chromosome count. Genome assembly sizes ranged from 12.1
and 12.7 Mb, and the number of predicted protein coding genes
ranged from 5,288 and 5,601, similar to other Candida species.
The correlation between the genome assembly size and the
number of predicted genes was surprisingly negative (n = 7,
r2 = 0.0725) (Muñoz et al., 2018). To date, the genome of clade
V has not been reported.
The seven chromosomes of C. auris have undergone
chromosomal rearrangements between clades. For example,
inversions and translocations of hundreds of kilobase genomic
regions have been reported between Clade I (isolate B8441) and
Clade III (isolate B11221) (Muñoz et al., 2018). More recent work
using long-read telomere-to-telomere sequencing has shown the
Clade II genome appears highly rearranged compared with the
other 3 clades, with 2 inversions and 9 translocations resulting
in a substantially different karyotype (Muñoz et al., 2019). It was
hypothesized that these rearrangements could potentially prevent
genetic exchange between those lineages (Muñoz et al., 2018).
However, a phylogenetically conserved (at least between C. auris,
C. haemulonii species complex, and C. lusitaniae) mating type
locus (MTL) is present in the C. auris genome, consisting of
a1 and a2 genes in MTLa isolates and a single α1 gene in the
MTLα isolates (Muñoz et al., 2018). Interestingly, Clade I and
Clade IV of C. auris isolates have so far all been MTLa, while
Clade II and Clade III have all been MTLα. The mating type of
Clade V has not yet been reported. The presence of a conserved
mating type suggests that C. auris can mate, despite a lack of clear
recombinants between or within clades.
Genomic variation between and within clades of C. auris
may have an impact on gene function. The four clades of
C. auris share an average pairwise nucleotide identity of 98.7%
(Muñoz et al., 2018). In terms of nucleotide diversity (pi), the
four clades of C. auris had a value of 0.0039 which is less
than C. neoformans var. grubii and more than the exclusively
clonal Trichophyton rubrum (Muñoz et al., 2018). In terms of
microevolution, Chow et al. (2018) found between 0 and 12
SNPs among clinical and screening cases in the United States
within a patient, and also similar numbers within the facility
during an outbreak. Comparisons between C. auris and its closest
relatives showed changes to genes linked to drug resistance
and virulence, including expanded families of transporters and
lipases (Muñoz et al., 2018). However, much work remains to
study positive selection between clades, and various features of
population genetics within clades – including the identification of
crossovers, effective population sizes, fixation indices, or evidence
for bottlenecking.
Given the rapid clinical emergence of C. auris, including the
newly identified Clade V in 2018 (Chow et al., 2019), the allelic
variation within the species remains unclear. Further sampling of
C. auris is clearly necessary, both in terms of screening historic
samples that may have been mischaracterized, as well as new
sampling efforts in both clinical and environmental settings.
The discovery of additional clades, and the identification of
clades with multiple mating types would assist in understanding
the evolution of C. auris. A greater understanding of C. auris’
phylogenetics and population genetics would also be achieved by
additional bioinformatic analysis – including a comprehensive
characterization of gene gain/loss events and selection of alleles
between or within those species or clades.
GENOMIC EPIDEMIOLOGY OF C. auris
Since 2009, five genetically diverse clades have been discovered
from India and Pakistan (South Asian; Clade I), Japan (East
Asian; Clade II), South Africa (African; Clade III), Venezuela
(South American; Clade IV) (Lockhart et al., 2017b) and most
recently in 2019, Iran (Clade V) (Chow et al., 2019). Over the
past decade, isolates of C. auris have also been detected across
all major continents, including elsewhere in Asia, Europe, the
Middle East, Africa, Australia, and North and South America
(Table 1). This nearly simultaneous and recent independent
emergence is both unprecedented and raises questions regarding
its origins and transmission events.
Genome sequencing of isolates from clinical environments
is revealing detailed insights into how C. auris is spreading
between continents, within countries, and even within wards
of hospitals and over time in patients. For example, between
2013 and 2017, 133 isolates (73 clinical cases and 60 screening
cases) from ten US states were collected and evaluated by
whole genome sequencing (Chow et al., 2018) and compared
to standardized case report forms and contact investigations,
including travel history and epidemiological links. Chow et al.
found that isolates were related to South Asian, South American,
African and East Asian isolates, indicating multiple clades of
C. auris were introduced into the United States, some of
which perhaps several times. Surprisingly however, only 7%
of the clinical cases had clear evidence of being acquired
through health-care exposures abroad, suggesting travel data
were lacking, the index patient with exposure were not identified,
or that the infection many may have been acquired from
other sources, perhaps including environmental sources. Chow
et al. found a similarly small number of SNPs (between 0
and 12) among clinical and screening cases within a patient
compared with those within a facility during an outbreak. The
low numbers of genomic variants indicate that there is local
and ongoing transmission of C. auris in the United States,
with most (82%) of the clinical isolates reported from hospitals
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TABLE 1 | C. auris has caused outbreaks across all major continents over the last decade.
Region Country Details Clade(s) Date Citation
Asia China 15 patients, 35 isolates (26 from urine, 4 catheter, 3
sputum, 1 blood, 1 fluid)
III 2011–2017 Tian et al., 2018
India 3 hospitals, 19 isolates I 2012–2015 Lockhart et al., 2017b
Japan 1 patient (external ear canal) II 2009 Satoh et al., 2009
Malaysia 1 hospital, 1 patient Unknown 2017 Mohd Tap et al., 2018
Pakistan 2 hospitals, 18 isolates I 2010–2015 Lockhart et al., 2017b
Singapore 1 hospital, 3 patients (all with recent hospitalizations in India
or Bangladesh)
Unknown 2012–2017 Tan and Tan, 2018
South Korea 61 patients (4 blood, 57 ear) from 13 hospitals II 1996–2018 Kwon et al., 2019
Europe Austria 1 case Unknown 2018 Kohlenberg et al., 2018
Belgium 1 case Unknown 2013–2017 Kohlenberg et al., 2018
France 2 cases Unknown 2013–2017 Kohlenberg et al., 2018
Germany 7 cases (6 from patients previously hospitalized abroad) I, III 2015–2017 Hamprecht et al., 2019
Norway 1 case Unknown 2013–2017 Kohlenberg et al., 2018
Russia 1 hospital (49 cases in an ICU) I 2016–2017 Barantsevich et al., 2019
Spain 79 isolates, 738 environmental samples Unknown 2017–2019 Ruiz-Gaitán et al., 2019
Switzerland 1 patient who was on holiday in Spain, transferred to
Switzerland hospital
Unknown 2017 Riat et al., 2018
The Netherlands 2 cases (both from patients previously hospitalized in India) I 2019 Vogelzang et al., 2019
United Kingdom 72 patients (colonization, candidaemia, vascular lines) I 2015–2016 Rhodes et al., 2018b
Middle East Iran 1 patient V 2018 Chow et al., 2019
Israel 2 hospitals, 5 patients Unknown 2014–2015 Ben-Ami et al., 2017
Kuwait 56 patients, 158 isolates Unknown 2014–2017 Khan et al., 2018
Oman 2 patients Unknown 2016–2017 Mohsin et al., 2017
Saudi Arabia 1 hospital, 2 patients I 2017–2018 Abdalhamid et al., 2018
United Arab Emirates 1 hospital, 1 patient Unknown 2017 Alatoom et al., 2018
Africa Kenya 1 patient III 2012 Heath et al., 2019
South Africa 1,576 cases III 2012–2016 Govender et al., 2018
Australia Australia 1 patient (a 65-year old with recent hospitalization in Kenya) III 2015 Heath et al., 2019
Americas Canada 1 patient (a 64-year old with a recent hospitalization in India) Unknown 2017 Schwartz and Hammond, 2017
Columbia 4 hospitals, 7 people colonized, 37 environmental samples IV 2015–2016 Escandón et al., 2019
Panama 1 hospital, 9 patients, 14 isolates Unknown 2016 Araúz et al., 2018
United States 10 US states (133 isolates; 73 clinical cases and 60
screening cases)
I, II, III, IV 2013–2017 Chow et al., 2018
Venezuela 1 hospital, 5 isolates IV 2012–2013 Lockhart et al., 2017b
located in New York and New Jersey (Chow et al., 2018;
Tracking Candida auris | CDC, 2020).
Outbreaks in Europe and Australia have also been attributed
to recent spread from other continents. For example, of the 7
cases of C. auris identified in Germany during 2015–2017, 6
were from patients previously hospitalized abroad (Hamprecht
et al., 2019). Whole-genome sequencing and epidemiologic
analyses revealed that all patients in Germany were infected
with different strains: five related to isolates from South Asia
(Clade I), and one related to isolates from South Africa (Clade
III) (Hamprecht et al., 2019). More recently (2019), the first
two cases of C. auris were reported in The Netherlands,
with both cases arising in patients that were treated in a
healthcare facility in India prior to admission. Indeed, genetic
analysis showed that these isolates also belonged to the South
Asian C. auris Clade I (Vogelzang et al., 2019). In Australia
in 2015, a 65-year-old man with a history of intensive
care treatment in Kenya in 2012, was diagnosed with the
South African Clade III of C. auris causing sternal osteomyelitis
(Heath et al., 2019).
The largest outbreak in the United Kingdom to date of
C. auris occurred between April 2015 and November 2016 in
the Royal Brompton hospital in London, which involved 72
separate patients (Schelenz et al., 2016). Using Oxford Nanopore
and Illumina sequencing technologies to gather genomic data on
those clinical isolates, Rhodes et al. placed the United Kingdom
outbreak in the India/Pakistan clade (Clade I), demonstrating
an Asian origin for the outbreak. Rhodes et al. (2018a) were
also able to estimate the timing for the most recent common
ancestor (MRCA) of those outbreak strains to late March 2015,
which was just weeks prior to the first patient identified with a
C. auris infection. Additionally, by using root-to-tip regression,
Rhodes et al. (2018a) estimated the evolutionary rate of the
C. auris nuclear genome to 5.7 × 10−5 substitutions per site per
year, a slower rate to the nuclear DNA of other related fungal
species in the Saccharomycetales such as Saccharomyces cerevisiae
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(5.7× 10−3), as well as more distantly related species such as the
Schizosaccharomyces pombe traditional beer strains (3.0× 10−3).
Multiple outbreaks of C. auris in Colombia between 2015 and
2016 led to a concerted effort to understand its epidemiology
within Colombian health-care clinics (Escandón et al., 2019). By
sampling infected patients, patient contacts, healthcare workers,
and the environment across 4 hospitals, they identified likely
sources of transmission events, including health-care workers,
and in the hospital environment. For all studied groups, the
swabbed body sites included: axillae, groins, nostrils and ears.
Samples were also taken from the mouth and rectum of
patients. Among patients, the axilla, groin, and rectum had the
highest positivity rate (2/7; 28% each). C. auris was isolated
from the hands of two healthcare workers and the groin of
another healthcare worker (Escandón et al., 2019). None of
the 4 patient contacts swabbed were positive for C. auris,
although the low sample size does not preclude this as a
mechanism of spread. C. auris was isolated from 37 of 322 (11%)
environmental samples, including a diverse range of hospital
equipment including on a stethoscope, hospital floor, body cables,
bed railing, mattresses, stretchers, bedpans, a closet, towel, cell
phone, mops, TV control, meal table, sink, toilet, wheelchair, and
a nurse’s shoe. The results demonstrate that contamination can
occur, and also that C. auris can survive on a variety of substances,
at least in the short term (Escandón et al., 2019). Unlike the
aforementioned European outbreaks, whole-genome sequencing
and phylogenomics showed that the genetic background of
isolates throughout the four hospitals were all similar (suspected
Clade IV), despite the four hospitals spanning 700 km across
Colombia. Isolates from the two northern Colombian hospitals
grouped into a sub-clade, while those from the two southern
hospitals grouped into a separate sub-clade, suggesting some
geographically defined population structure in the country, and
possibly endemism.
Since it was first discovered in Tokyo Metropolitan Geriatric
Hospital (Tokyo, Japan) in 2009 (Satoh et al., 2009), C. auris
has caused hospital acquired infections and outbreaks across
all main continents including Asia, Europe, Africa, Australia,
North America and South America. Given the recency of these
outbreaks, further outbreaks across the world in the upcoming
decade appear likely, unless concerted mitigation efforts are
made (Escandón et al., 2019; Ong et al., 2019). It is also
likely that cases are being misidentified (Chatterjee et al., 2015;
Govender et al., 2018) or undetected, especially across Sub-
Saharan Africa, South America and Eastern Europe where there
are currently few reports (Ong et al., 2019). Exemplifying this
is how common C. auris has become in some hospitals from
regions with few additional reports of cases (van Schalkwyk et al.,
2019). For example, in the Aga Khan University Hospital in
Nairobi, Kenya between 2010 and 2016, C. auris was the most
common cause of candidemia (38% of 201 patients) (Adam
et al., 2019), suggesting that other hospitals in Kenya and
in neighboring countries are likely to also harbor C. auris.
Necessary steps to better understanding the epidemiology of
C. auris will therefore include greater sampling and reporting
from regions that underreported C. auris cases, a transition
away from unreliable diagnostic methods, and further genomic
analysis describing the population genetics of the various
lineages, all of which may reveal its geospatial origin and
subsequent spread.
THE EMERGENCE OF C. auris
To date, the earliest reports of C. auris have been from a Clade
II isolate in 1996, retrospectively from a case of misidentified
nosocomial fungemia in South Korea (Lee et al., 2011). The
species was first described over 10 years later from a case
in Japan (Satoh et al., 2009), and simultaneously arising in
South Africa with a Clade III isolate also from 2009 (Govender
et al., 2018). C. auris has not been detected earlier than 2009
by The SENTRY Antifungal Surveillance Program, which has
been collecting consecutive invasive Candida isolates from 135
participating medical centers in North America, Europe, Latin
America and the Asia-Pacific regions since 1997 (Pfaller et al.,
2019). However, molecular clock estimates from 304 worldwide
genomes date the most recent common ancestor of each of the
four clades within the last 339 years, and outbreak isolates from
Clades I, III, and IV to 34–35 years ago (∼10 years prior to first
being detected) (Chow et al., 2020). While the details of its origin
remain unclear, C. auris is not the only fungal pathogen to have
recently clinically emerged. Indeed, a variety of phylogenetically
diverse emerging fungal pathogens are rapidly increasing in
their incidence, geographic or host range and virulence (Morse,
1995; Farrer and Fisher, 2017). Recently highlighted examples
include the emergence and increasing incidence of a separate
ascomycete responsible for human infections: Emergomyces
africanus (Dukik et al., 2017), the newly-described chytrid fungus
Batrachochytrium salamandrivorans causing rapid declines of fire
salamanders across an expanding region of northern Europe
(Farrer, 2019), and the basidiomycete fungus Cryptococcus gattii
expanding its range into non-endemic environments with a
consequential increase of fatal disease in humans (Fraser et al.,
2005; Byrnes et al., 2010).
One suggestion for the absence of C. auris isolates prior to
1996 is that it has only recently become part of the human
microbiome, and has either recently acquired sufficient virulence
to cause invasive infections or been newly introduced into
human populations in which invasive Candida infections can
be identified (Jackson et al., 2019). For example, recent genetic
recombination, hybridization, or other biological changes could
potentially increase the organism’s transmissibility or virulence
(Jackson et al., 2019). However, for this hypothesis to hold, such
genetic changes would need to have occurred across all clades of
C. auris recently.
One line of inquiry to understand the recency of the
emergence has been to re-screen isolates taken prior to 2009
that may have been misdiagnosed as other Candida species.
Indeed, C. auris has been misdiagnosed as its closest relatives
C. haemulonii or C. pseudohaemulonii (Chatterjee et al., 2015),
species which have even been identified alongside C. auris in the
same month in the same hospital (Ben-Ami et al., 2017). Lee
et al. (2011) identified the oldest known case of C. auris from
South Korea, which dates to 1996, belongs to Clade II, and had
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been misidentified as C. haemulonii by Vitek 2. Another clinical
isolate originally characterized as C. haemulonii from a hospital
in South Africa, was later shown to be a Clade III isolate of
C. auris (Govender et al., 2018). This isolate was taken from a
patient in 2009 demonstrating independent emergences in 2009
of at least two of the C. auris lineages (Clade II and Clade III).
A recent study comparing 204 genomes of C. auris using Bayesian
molecular clock phylogenetics estimated the origin of each of the
four clades within the last 339 years, and outbreak clusters (Clade
I, III, and IV) originating 34–35 years ago (Chow et al., 2020),
suggesting more historic samples were not identified.
The spread of C. auris within and between hospital settings
has been clearly demonstrated by at least clades I, III and IV (e.g.,
Chow et al., 2018; Rhodes et al., 2018b; Escandón et al., 2019),
so it is possible that abiotic factors could explain the emergence.
For example, human activities such as deforestation, expansion of
farmland, and coastal ecosystem disruption could have allowed
an ecological jump (Jackson et al., 2019). Indeed, C. auris’ closest
relatives include C. ruelliae from flowers of the Ruellia species
(Saluja and Prasad, 2008), and C. haemulonii that can also cause
clinical infections but also found in the GI tract and skin of
marine animals (van Uden and Kolipinski, 1962; Khan et al.,
2007). Furthermore, C. auris has been shown to persist on a wide
variety of hospital equipment (Escandón et al., 2019). It therefore
seems likely that C. auris may also have an environmental
niche (plants or aquatic). The widespread use of fungicides,
especially triazoles in agriculture could have been responsible
for C. auris to become more prominent in the environment, as
it shows high levels of antifungal resistance. At the same time,
increased human travel, trade or other anthropogenic factors may
have simply led to the globalization and emergence of C. auris
(Jackson et al., 2019).
C. auris is able to grow (albeit slowly) at 42◦C, while isolates
from close relatives (C. haemulonii, C. pseudohaemulonii or
C. heveicola) were unable to grow at this temperature (Satoh
et al., 2009). C. auris’ thermotolerance enables it to cause invasive
candidemia, including tolerating the fever response (Jackson
et al., 2019), but may also enable it to sustain body temperatures
of other animals including birds (Casadevall et al., 2019). For
example, pigeons body temperature can be up to 44◦C during
flight (Aulie, 1971), compared with only a few degrees above 37◦C
during exercise for humans (Gleeson, 1998). Similarly, sea birds
may serve as reservoirs for indirect transmission of drug-resistant
Candida species, such as C. glabrata, to humans (Al-Yasiri et al.,
2016; Casadevall et al., 2019). C. auris is also able to survive
high salt concentrations (broth containing 10% NaCl), which
might allow it survive environmentally including hypersaline
desert lakes, salt-evaporating ponds, or tidal pools (Jackson et al.,
2019). Thus, C. auris is thought likely to survive both in the
environment, as well as colonizing human skin. On skin it is
likely to compete with other commensals such as Malassezia,
although studies on C. auris interactions with bacteria or other
fungi are lacking.
The thermotolerance of C. auris has led to the hypothesis
that its emergence may be linked to climate change and global
temperature changes, and may even be the first example of a
new pathogenic fungus emerging from human-induced global
warming (Casadevall et al., 2019). Indeed, it has been proposed
that as the gap between the environmental temperature and
human body temperature narrows, new fungal diseases of
mammals will increase (Garcia-Solache and Casadevall, 2010).
Casadevall et al. (2019) suggest a number of factors that supports
the hypothesis of a climate change emergence, including that
C. auris can grow on skin but not anaerobically in the gut
(suggesting a recent environmental source), the constitutive
overexpression of heat shock protein HSP90, and the inability
of many relatives to grow at high temperatures. C. auris
clades I, II, III, and IV differ by an average of 1.3% average
pairwise nucleotide identity (Muñoz et al., 2018). Although
a time to most recent common ancestor of multiple clades
has not yet been predicted, the ancestor to all clades almost
certainly predates industrial era warming, which begun in
1800 AD (Abram et al., 2016). Given that all known clades
of C. auris are able to colonize skin and cause infections,
its ability to colonize these niches are more likely to be
an evolutionary conserved trait, rather than five independent
recent trait acquisitions. It nevertheless remains to be shown if
climate change had a role to play in exposing each clade into
an alternative niche they already had the ability to colonize
(Casadevall et al., 2019).
Further environmental sampling, genome sequencing and
metagenomics studies focusing on fungi are necessary to identify
and confirm environmental sources of C. auris. Further genomic
epidemiology studies, including on the genetic diversity within
each clade will help to find older natural populations that could
indicate the progenitor of C. auris. Clade II (East Asian clade)
exhibits higher genetic diversity than the other clades (Jackson
et al., 2019), although it also exhibits large karyotypic variation
and loss of sub-telomeric regions, suggesting it is not ancestral
to Clade I, III and IV. The discovery of further ecological
niches and the geographical origin will be important to prevent
similar emergences in future as well as identify and mitigate
emergence of new clades of C. auris that have the potential to
cause outbreaks.
ANTIFUNGAL TREATMENT OF C. auris
Treating invasive fungal infections is a considerable challenge
due to the limited number of available antifungal agents. The
five major antifungal drug classes that are used in hospital
settings are azoles, allylamines, polyenes, echinocandins and
nucleoside analogs (Bidaud et al., 2018). To date, there are only
a few alternative antifungal agents (de Oliveira Santos et al.,
2018). While the efficacy of some antifungal classes is highly
dependent on the site of infection due to their tissue penetration
properties (Felton et al., 2014), other classes of antifungals
(i.e., polyenes) often lead to serious side effects such as renal
injury or cardiomyopathy (Bandeira et al., 2016), primarily due
to conserved or structural similarities in drug targets such as
cholesterol and ergosterol (Kamiñski, 2014). Given the lack of
treatment options, the emergence of fungal resistance to even
one of the major drug classes is very alarming, as it makes the
infection considerably more challenging to treat.
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TABLE 2 | Candida auris resistance patterns.
Samples Resistance threshold
Drug category Drug Method Resistant no used (µg/mL) References
Azoles Fluconazole CLSI 93% 54 32 Lockhart et al., 2017b
CLSI 86% 123 32 Arendrup et al., 2017
EUCAST 96% 123 32 Arendrup et al., 2017
CLSI 90% 320 32 Chowdhary et al., 2018
Voriconazole CLSI 54% 54 2 Lockhart et al., 2017b
CLSI 33% 123 2 Arendrup et al., 2017
EUCAST 15% 123 2 Arendrup et al., 2017
CLSI 39% 90 2 Kathuria et al., 2015
Vitek 2 29% 90 2 Kathuria et al., 2015
Etest 28% 90 2 Kathuria et al., 2015
CLSI 15% 320 2 Chowdhary et al., 2018
Isavuconazole CLSI 4% 123 2 Arendrup et al., 2017
EUCAST 4% 123 2 Arendrup et al., 2017
Itraconazole CLSI 0% 54 2 Lockhart et al., 2017b
CLSI 1% 123 2 Arendrup et al., 2017
EUCAST 0% 123 2 Arendrup et al., 2017
CLSI 6% 320 1 Chowdhary et al., 2018
Posaconazole CLSI 0% 54 2 Lockhart et al., 2017b
CLSI 2% 123 2 Arendrup et al., 2017
EUCAST 0% 123 2 Arendrup et al., 2017
Polyenes Amphotericin B CLSI 35% 54 2 Lockhart et al., 2017b
CLSI 16% 90 2 Kathuria et al., 2015
Vitek 2 100% 90 2 Kathuria et al., 2015
Etest 1% 90 2 Kathuria et al., 2015
CLSI 8% 320 2 Chowdhary et al., 2018
CLSI 10% 123 2 Arendrup et al., 2017
EUCAST 0% 123 2 Arendrup et al., 2017
Nystatin CLSI 100% 320 2 Chowdhary et al., 2018
Echinocandins Anidulafungin CLSI 2% 320 8 Chowdhary et al., 2018
CLSI 6% 123 8 Arendrup et al., 2017
EUCAST 0% 123 8 Arendrup et al., 2017
CLSI 7% 54 8 Lockhart et al., 2017b
Caspofungin CLSI 2% 320 8 Chowdhary et al., 2018
CLSI 3% 90 8 Kathuria et al., 2015
Vitek 2 0% 90 8 Kathuria et al., 2015
Etest 0% 90 8 Kathuria et al., 2015
CLSI 7% 54 8 Lockhart et al., 2017b
Micafungin CLSI 2% 320 8 Chowdhary et al., 2018
CLSI 7% 54 8 Lockhart et al., 2017b
CLSI 6% 123 8 Arendrup et al., 2017
EUCAST 6% 123 8 Arendrup et al., 2017
Nucleoside analogs 5-Flucytosine CLSI 6% 54 128 Lockhart et al., 2017b
Allylamines Terbinafine CLSI 100% 320 2 Chowdhary et al., 2018
Prior to publishing C. auris tentative resistance thresholds, various research groups used different concentrations to determine the resistance of their isolates. Their
choices were based on a comparison of the treatment outcomes associated with drug exposure observed in C. auris and in other Candida spp. infections.
It is of considerable concern to health authorities that the
emergent C. auris includes isolates that are resistant to all
antifungals (Warris, 2018). C. auris isolates are resistant to
fluconazole, the major drug in treating candidemia, with MIC
values> 64 µg/mL (Chowdhary et al., 2018; Warris, 2018). Other
azoles such as voriconazole show variable antifungal activity
(Table 2). While more than 95% of isolates from India were
resistant to a topical allylamine, terbinafine (Chowdhary et al.,
2018), currently UK strains remain susceptible to terbinafine
and polyene nystatin (Sarma and Upadhyay, 2017). Almost one-
third of isolates observed so far were resistant to amphotericin B
(a polyene used as a last resort drug) (Warris, 2018). Although
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TABLE 3 | Tentative MIC breakpoints of C. auris defined by CDC (Antifungal
Susceptibility Testing and Interpretation, 2019).
Drug class Drug Tentative MIC breakpoint (µg/mL)
Azoles Fluconazole ≥32
Azoles Other azoles N/A
Polyenes Amphotericin B ≥2
Echinocandins Anidulafungin ≥4
Echinocandins Caspofungin ≥2
Echinocandins Micafungin ≥4
the nucleoside analog 5-flucytosine successfully treated more
than 95% of C. auris infection cases in vitro (Lockhart et al.,
2017a; Osei Sekyere, 2018), it is not used extensively as therapy
because resistance arises rapidly, potentially during treatment
(Rhodes et al., 2018a), and it elicits toxic effects on bone
marrow that may lead to death in immunosuppressed patients
(Vermes et al., 2000). Between 2 and 7% of C. auris isolates have
developed resistance to echinocandins (Lockhart et al., 2017b;
Chowdhary et al., 2018), one the newest classes of antifungal
drug to be developed (Sucher et al., 2009). Reported adverse
effects of echinocandin therapy are generally mild and include
nausea and dose-related elevation of liver aminotransferases
levels (Aguilar-Zapata et al., 2015) and therefore, this group of
drugs is still the most effective for treating the majority of C. auris
infections. Resistance to all three common antifungal classes used
as therapy (azoles, polyenes and echinocandins) was observed
in 4% of C. auris outbreak samples in North America from
2012–2015 (Lockhart et al., 2017b).
Although C. auris is typically multidrug-resistant, levels of
susceptibility to various drugs differ greatly between isolates
and clades (Kean and Ramage, 2019). To find the most suitable
drug candidate, susceptibility is typically measured over the
period of 24 h, when the fungus grows in the presence
of a drug concentration gradient. If the observed minimal
inhibitory concentration (MIC) is greater than the resistance
MIC breakpoint, the examined isolate is considered resistant to
the drug. Tentative susceptibility MIC breakpoints for C. auris
established by CDC are shown in Table 3. Currently, these
C. auris susceptibility breakpoints should be treated as a general
guide as the connection between them and clinical outcome
is not known yet.
Importantly, some Candida such as C. albicans exhibit drug
tolerance defined as the ability of a fraction of a population to
grow above the population resistance level (Rosenberg et al.,
2018). The presence of highly tolerant sub-populations may lead
to persistent candidemia that is associated with a mortality rate
higher than 50% (Hammoud et al., 2013) despite appropriate
treatment (Alatoom et al., 2018). In vivo data suggest that
reducing drug susceptibility without affecting the resistance of
the population may be possible using adjuvant drugs (Rosenberg
et al., 2018). Adjuvants such as the antidepressant fluoxetine that
impairs biofilm development (Oliveira et al., 2018) or Hsp90
inhibitor called radicicol that blocks stress responses (Rosenberg
et al., 2018) have been shown to clear tolerance without
altering the susceptibility level when given in combination
with fluconazole in C. albicans (Rosenberg et al., 2018). Future
clinical control trials are required to confirm the effectiveness
of adjuvants before being considered for inclusion as a possible
treatment protocol.
MECHANISMS OF DRUG RESISTANCE
IN C. auris
C. auris has evolved a range of molecular drug-resistance
mechanisms which are shown in Figure 1. They include
(1) Drug target mutation (Bidaud et al., 2018), (2) drug target
overexpression (Bhattacharya et al., 2019), (3) changes in drug
uptake and efflux (Muñoz et al., 2018), (4) activation of stress
response pathways (Kim et al., 2019), and (5) biofilm formation
(Kean et al., 2018). By aggregating into a colony and forming
a biofilm, Candida spp. increase their resistance to all currently
available antifungals by up to 1000-fold (Taff et al., 2013). Some
of the key regulators of fungal biofilm dispersion, antibiotic
tolerance, and cell wall remodeling are molecular chaperones
belonging to Hsp90 family (Robbins et al., 2011; Leach et al.,
2016). In C. auris, these proteins were found to promote cell-
wall integrity signaling and stress responses related to azoles
administration thereby contributing to the evolution of drug
resistance (Kim et al., 2019).
Azoles are an important group of antifungal agents that were
first developed in the late 1960s, and function by inhibiting the
synthesis of ergosterol, a key component of the fungal membrane,
thereby preventing growth and proliferation (Ghannoum and
Rice, 1999). Since the action of azoles is largely dependent
on the affinity of the drug to the active site of Erg11p, any
mutations that affect the active site of the enzyme may lead to
the development of drug resistance (Berkow and Lockhart, 2017).
Such resistance mechanisms have been observed in C. albicans, in
which more than 140 ERG11 mutations have been identified to
date (Debnath and Addya, 2014). These mutations accumulated
in three regions of the ERG11 gene (Marichal et al., 1999).
Bioinformatic analysis of these substitutions combined with
3D modeling showed that most of them are located near the
predicted catalytic center or on elements of the fungus-specific
external loop (Whaley et al., 2017). Many of the described
mutations can also be found in C. auris, but not all have the
same effects (Muñoz et al., 2018). In both species, amino acid
substitutions at F126L, Y132F, K143R result in azole resistance
(Morio et al., 2010; Chowdhary et al., 2018; Healey et al., 2018),
with Y132F the most widespread mutation associated with azole
resistance (Chow et al., 2020). Another mechanism of azole
resistance is the overexpression of Erg11p, which can be caused
either by increasing the number of ERG11 transcription factors
such as Upc2p or by duplicating ERG11 (Bhattacharya et al.,
2019). In both cases, the high concentration of azole target dilutes
the effects of drug activity (Muñoz et al., 2018).
The activity of azoles can be also reduced by decreasing the
concentration of antifungals in the cell by means of efflux pumps.
Recently, 20 ABC transporters that are putative efflux pumps
have been identified in the C. auris genome, strain-type CBS
10913T (Wasi et al., 2019). Two drug transporters (CDR1 and
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FIGURE 1 | Mechanisms of drug action and resistance observed in C. auris. (A) The main mechanisms of antifungals that disrupt the cell membrane or cell wall.
(B) In the nucleus, 5-flucytosine inhibits the synthesis of fungal DNA and RNA. (C) Mechanisms of antifungal resistance to drugs that damage the cell membrane or
cell wall.
MDR1) that have primarily been studied in C. albicans have
orthologs in C. auris, and these orthologs are overexpressed in
azole-resistant C. auris (Rybak et al., 2019). CDR1 is an ABC
transporter that confers azole-derived compounds resistance,
while MDR1 is a Major Facilitator Superfamily (MFS) pump
and a member of the multidrug resistance family which is
responsible for fluconazole resistance (de Oliveira Santos et al.,
2018). Rybak et al. demonstrated that deletion of CDR1
restored susceptibility of highly resistant C. auris isolates to
fluconazole. Furthermore, domains associated with transporters
such as OPT and glutathione were found to be significantly
enriched in C. auris, C. haemulonii, C. duobushaemulonii, and
C. pseudohaemulonii when compared to related species (Muñoz
et al., 2018). Oligopeptide transporters (OPT) are small peptide
transporters expression of which is upregulated in C. albicans
upon administration of azoles (Muñoz et al., 2018). Similarly,
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glutathione transporters may contribute to azole resistance by
exporting oxidized glutathione derivatives out of the cell and
thereby protecting the cell against oxidative damage elicited by
the drugs (Maras et al., 2014).
Polyenes are a commonly used group of drugs used to treat
C. auris infections. The most known polyene, amphotericin B,
binds membrane-bound ergosterol, causing pores to form in
the fungal membrane through which small molecules leak to
the outside of the cell (de Oliveira Santos et al., 2018). The
release of intracellular constituents such as sugars, potassium
or calcium strongly contributes to cell death (de Oliveira
Santos et al., 2018). We are not aware of any mechanism
of polyenes resistance reported for C. auris so far, which
would presumably be analogous to ERG3 dependent alternations
in sterol synthesis observed in C. albicans or alternations
in cell membrane sterol composition (Taff et al., 2013).
However, in 2018, Muñoz et al. (2018) showed that intrinsic
transcription of multidrug transporters in C. auris was higher
when compared to susceptible and resistant isolates and that
upon administering Amphotericin-B, eight genes including
OPT1-like transporter (high-affinity glutathione, tetra- and
pentapeptides transporter), CSA1 (conserved cell wall protein
1 involved in biofilm formation), MET15 (sulfhydrylase) and
ARG1 (argininosuccinate synthase) were upregulated. In 2019,
another study identified five novel mutations that associate
strongly with amphotericin B resistance in Colombian C. auris
(p ≤ 0.001). Four of the identified mutations fall within protein-
coding regions (Escandón et al., 2019). One of the mutations
occurs within FLO8, a transcription factor that is required for
virulence and biofilm formation in C. albicans (Escandón et al.,
2019). Another one is located within a predicted transmembrane
protein that could contribute to drug resistance (Escandón et al.,
2019). Drug transporters overexpression upon administering
amphotericin B was also observed by Wasi et al. In their
study, they found 8.7-fold increase in expression of a homolog
of CDR6 ABC transporter (Wasi et al., 2019). In the search
for more robust drugs and drug targets, we urgently need to
better understand the structure and function of drug pumps in
pathogenic fungi, as well as how allelic diversity and mutations
can affect drug efficacy.
Echinocandins act through the non-competitive inhibition of
FKS1 gene product called β(1→3) glucan synthase, which results
in stopping production of glucan. Because of depleted glucan, the
fungal cell becomes weak and prone to osmotic stress (de Oliveira
Santos et al., 2018). C. auris’ resistance to echinocandins has been
linked to mutations S639F, S639P and S639Y that occur in the
highly conserved hot-spot 1 of FKS1 and decrease the sensitivity
of the enzyme to the drug (Bidaud et al., 2018; Hou et al., 2019).
S639P in FKS1 was recently shown to be the most widespread
mutation associated with echinocandin resistance (Chow et al.,
2020). A recent multi-omics analysis revealed that although the
cell wall remodeling enzymes concentration was lower in C. auris
when compared to C. albicans, in a drug-resistant C. auris isolate
(MIC fluconazole:> 256µg/mL, MIC caspofungin: 2µg/mL) cell
wall integrity proteins were upregulated, suggesting that the cell
wall metabolism can be adjusted in response to drug treatment
(Zamith-Miranda et al., 2019).
Little is known about C. auris resistance mechanisms to
other drug classes such as nucleoside analogs or allylamines
(Jeffery-Smith et al., 2018). The nucleoside analogs class contains
only 5-flucytosine (5FC) – a drug inhibiting RNA and DNA
synthesis in pathogenic fungi (Rapp, 2004). One amino acid
substitution (F211I) that is associated with 5FC resistance has
been identified in the conserved FUR1 sequence encoding
uracil phosphoribosyltransferase (Rhodes et al., 2018b). However,
further work is required to understand how such polymorphisms
may affect the functioning of the enzyme, which is responsible
for the conversion of 5-fluorouracil into 5-fluoro-UMP acid
monophosphate. For allylamines, a homolog of ABC transporter
CDR6 was found to be significantly upregulated in drug-resistant
C. auris following terbinafine treatment (Wasi et al., 2019).
DETECTION AND NOVEL TREATMENTS
OF C. auris
Successful treatment of C. auris infection depends heavily on its
accurate identification. In the early stages of infection, symptoms
are non-specific and blood cultures typically remain negative
(Pfaller and Castanheira, 2016). The resulting delay in diagnosis
directly translates to decreased chances of survival; in the study
of C. auris outbreak in a European hospital between 2016 and
2017, 41% of patients died within 1 month from infection
(Ruiz-Gaitán et al., 2018).
C. auris does not possess phenotypic features that could easily
distinguish it from other Candida spp. (Osei Sekyere, 2018).
Depending on the strain it appears purple, red, pink or white
on CHROMagar (Kordalewska and Perlin, 2019b) but unlike
most types of yeast, it is able to withstand high temperatures
(42◦C) (Osei Sekyere, 2018). Many misidentifications related to
automated tools such as VITEK 2, BD Phoenix, RapID Yeast Plus,
API 20C have been reported to date. Ambaraghassi et al. (2019)
demonstrated that VITEK 2 was unable to consistently identify
C. auris and that the identification depended on the clade. While
the tool identified correctly the South American clade (n = 8), its
accuracy was variable for isolates from the African (7%, n = 10)
and East Asian clades (0%, n = 4) (Ambaraghassi et al., 2019).
Genomics analysis showed that the low identification rate was
likely due to the deletion of the L-rhamnose 7-gene cluster in all
clades except for the South African clade (Ambaraghassi et al.,
2019). As one of 20 tests performed by the VITEK 2 platform
is based on the ability of the tested organism to assimilate
L-rhamnose (Graf et al., 2000, 2), the deletion of L-rhamnose gene
cluster can have an impact on identification results. The most
reliable way to identify C. auris without genomic sequencing
is MALDI-TOF MS (Vatanshenassan et al., 2019). Although
not all reference databases contain its protein profile, a free
supplemental update is available from MicrobeNet (Lockhart
et al., 2017a). A variety of groups have also had success with
sub-genomic methods such as sequencing D1-D2 region of 28s
ribosomal DNA (rDNA) or internal transcribed spacer region of
rDNA (Jeffery-Smith et al., 2018). Unfortunately, access to such
tools is limited in many community hospitals.
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TABLE 4 | New antifungals in trials.
Company Drug Trial (Phase) Activity References
Amplyx Fosmanogepix (APX001)* C. auris (Ib), Candidemia (II) Gwt1 inhibitor (novel) Hager et al., 2018
Synexis Ibrexafungerp* C. auris (III) Glucan synthase inhibitor
(novel, orally available)
Berkow and Lockhart,
2017; Larkin et al., 2019
NQP 1598 VT-1598 C. auris (I) CYP51 (Erg11p) inhibitor Wiederhold et al., 2019
Mycovia VT-1161 Candidiasis (III) CYP51 (Erg11p) inhibitor Brand et al., 2018, p. 2
Cidara Rezafungin Candidemia (III) Long half-life echinocandin Lepak et al., 2018
*Fosmanogepix (Hodges et al., 2017) and Ibrexafungerp (Juneja et al., 2019) are available in an emergency in fungi research centers such as University Hospital Graz
(Graz), University Hospital Innsbruck (Innsbruck), Radboud University (Nijmegen) and University Hospital of Manchester (Manchester).
The necessity for expeditious identification of C. auris in order
to effectively treat patients and prevent outbreaks combined with
slow current standard laboratory techniques creates a pressing
need for new diagnostic tools that could rapidly recognize C. auris
and its drug resistance patterns. Most of biochemical automated
systems and MALDI-TOF MS require cultures, which can take up
to 2 weeks to obtain (Kordalewska and Perlin, 2019a). To identify
C. auris directly from skin swabs, molecular-based assays such
as loop-mediated isothermal amplification (LAMP), T2 magnetic
resonance and PCR/qPCR have been applied (Kordalewska
and Perlin, 2019b). Since DNA can be isolated directly from
the clinical sample, these tests can deliver diagnostic results
within several hours (Kordalewska and Perlin, 2019a), which
dramatically increases the probability of survival, given that the
time window appropriate for initiating appropriate antifungal
therapy in Candida bloodstream infection was estimated to 12 h
(Morrell et al., 2005).
The choice of optimal C. auris treatment method depends on
both the patient (age, previous use of antifungal medications,
infection site, immune status) and the attacking pathogen (strain,
possible biofilm formation, drug resistance patterns) (Dodgson
et al., 2004; Felton et al., 2014; Bidaud et al., 2018; Moser
et al., 2019). The mainstay of therapy is antibiotics. In adults,
it is encouraged to begin the therapy with echinocandins even
before receiving susceptibility test results (Bidaud et al., 2018).
Amphotericin B should be considered for neonates, infants
below 2 months of age and as a single or in combination
with micafungin when monotherapy with echinocandins fails
(Alfouzan et al., 2019; Park et al., 2019). Among azoles, the
highest antifungal activity has been observed for itraconazole,
isavuconazole and posaconazole (Bidaud et al., 2018), which
are sometimes used as a secondary therapy. When voriconazole
and micafungin are taken together they show greater effects
when compared to the sum of the effects of these drugs taken
separately (Cortegiani et al., 2018). While systemic antibiotic
treatment is not advised for people colonized with C. auris,
control measures should be followed in all cases (Bidaud et al.,
2018). Invasive devices such as catheters and ventricular shunts
should be removed as soon as they are no longer needed as they
may be infected with a biofilm (Bidaud et al., 2018).
C. auris develops resistance rapidly while the patient is being
treated and therefore it is crucial to use the available antifungals
for the right amount of time and in the right dose (Jeffery-
Smith et al., 2018). Close monitoring of drug susceptibility is
necessary in both infection and colonization cases in order
to identify changes in antifungal resistance (Bidaud et al.,
2018). Furthermore, special care is required when administering
fungistatic drugs as they may provide the opportunity for
resistance to emerge (Berkow and Lockhart, 2017). A small
number of new anti-fungal agents are showing successes in
clinical trials that may become available for wider use in hospital
settings in the upcoming years (Table 4).
MECHANISMS OF VIRULENCE IN
C. auris
Stress resistance, thermotolerance, adherence to host cells, and
immune evasion are important virulence traits across Candida
species. Investigations of C. auris virulence traits often draw
comparisons to the extensively-studied pathogen, C. albicans.
The C. auris genome encodes several orthologs of known
virulence factors in C. albicans including genes associated with
biofilm formation, antifungal drug resistance, and phenotypic
switching (Muñoz et al., 2018). Recent virulence, transcriptome,
and other studies are highlighting how these conserved fungal
virulence mechanisms may contribute to C. auris’ emergence as a
nosocomial pathogen (Figure 2).
Virulence
Conflicting reports abound regarding C. auris’ virulence in vivo
compared to other pathogenic Candida species. Depending
on the isolate and infection model used, C. auris may be
regarded as more virulent (Sherry et al., 2017), as virulent
(Borman et al., 2016; Fakhim et al., 2018), or less virulent (Ben-
Ami et al., 2017; Wang et al., 2018) than C. albicans in
murine and invertebrate infection models. In studies utilizing
the Galleria mellonella invertebrate infection model, C. auris
isolates exhibit similar virulence phenotypes, or even slightly
more virulent phenotypes, than C. albicans (Borman et al., 2016;
Sherry et al., 2017).
Investigators have used immunocompetent and immuno-
compromised murine models of invasive candidiasis to evaluate
C. auris virulence. In immunocompromised animals infected
with Israeli C. auris clinical isolates, infection lead to rapid
death within 5 days, but overall C. auris exhibited decreased
virulence and lower kidney fungal burdens compared to
C. albicans strain CBS 8837 (Ben-Ami et al., 2017). One study
with immunocompetent animals established that two clade II
C. auris isolates had similar virulence outcomes compared to
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FIGURE 2 | Putative C. auris virulence factors. Key orthologs of C. albicans
virulence factors that are transcriptionally induced during C. auris growth at
37◦C are indicated by orange text within each box. C. auris Hog1 is the only
conserved ortholog with C. albicans that has been experimentally confirmed
to play a role in virulence.
one C. albicans clinical isolate (IFRC 1442) (Fakhim et al.,
2018), while a study in China determined that the first C. auris
isolate identified in China was significantly less virulent than
the standard C. albicans laboratory strain SC5314 (Wang et al.,
2018). To date, data from murine infection models are difficult to
interpret due to inconsistencies in the C. auris and comparator
C. albicans strains employed between studies. Consequently,
it is not currently possible to speculate whether C. auris or
individual clades of C. auris are generally more, less, or similarly
virulent during mammalian infection compared to the prototypic
pathogen C. albicans.
Phenotypic and genotypic variability between different
C. auris isolates are plausible explanations for the discrepancies
described in virulence studies. This variability is somewhat
unsurprising given the broad geographical distribution and
genetic diversity among clades of C. auris outbreaks, but also
highlights our poor understanding of C. auris pathogenesis.
Further characterization of virulence determinants, some of
which will be discussed in this section, are important for
understanding the virulence potential of this organism. The
field would significantly benefit from standardizing virulence
investigations by adopting one major C. albicans comparison
strain and utilizing high-throughput in vitro methodologies to
rapidly identify type strains for each C. auris clade that are
suitable for comparative in vivo studies.
Lytic Enzymes
Lytic enzymes, such as secreted aspartyl proteases (SAPs), lipases,
phospholipases, and hemolysins, are important virulence factors
in human pathogenic fungi (Chaffin, 2008). These enzymes
facilitate host cell invasion and tissue destruction by C. albicans
(Polke et al., 2015). C. auris encodes orthologs of many known
C. albicans lytic enzymes, including secreted aspartyl proteases,
secreted lipases, and phospholipases (Chatterjee et al., 2015).
Several studies have demonstrated lytic activity for C. auris
SAPs (Yue et al., 2018), phospholipases (Larkin et al., 2017),
and hemolysin (Kumar et al., 2015), but little is known about
how the expression profiles of these enzymes compare to their
C. albicans orthologs in vitro or in vivo. Two SAP orthologs were
transcriptionally induced in C. auris filamentous cells compared
to yeast cells (Yue et al., 2018), but their relative roles in virulence
remain unknown. Further molecular and virulence studies are
necessary to determine the importance of lytic enzymes to
C. auris’ infection strategy.
Filamentous Growth
While filamentation is integral to C. albicans virulence (Zheng
et al., 2004), its contribution to C. auris virulence is less certain
given that in vivo evidence to date has identified only yeast cells
in animal tissues (Ben-Ami et al., 2017). Interestingly, in vivo
passage can confer a filamentation-competent (FC) phenotype,
but FC and yeast cells have comparable virulence in mice
suggesting that filamentation is dispensable for C. auris virulence
(Yue et al., 2018).
In vitro C. auris filamentation occurs under a restricted
and/or atypical set of growth conditions compared to C. albicans
(Wang et al., 2018; Yue et al., 2018). Like C. albicans, Hsp90
depletion or pharmacological inhibition induces filamentous
growth and the expression of adhesins and cell wall genes
orthologous to C. albicans filament-associated genes (Kim et al.,
2019). During FC-triggered filamentous growth, orthologs of
C. albicans CPH1 and FLO8, which encode transcriptional
regulators of filamentous growth, were induced in C. auris
filamentous cells compared to yeast (Yue et al., 2018). In
addition, orthologs of C. albicans filament-associated genes
were upregulated during C. auris filamentation, including the
G1 cyclin-related gene HGC1 and glycosylphosphatidylinositol
(GPI) anchored gene ALS4. However, there were key differences
in the filamentation transcriptomes for C. auris relative to
C. albicans. EFG1, an important transcriptional regulator of
filamentation in C. albicans, was down-regulated in C. auris
filamentous cells. Other C. albicans filament-associated cell
wall orthologs were preferentially expressed during C. auris
yeast growth (PGA34, PGA38, and PGA58) (Yue et al., 2018).
Thus, while C. auris shares some transcriptomic aspects of the
C. albicans filamentous growth program, the role of C. auris
filamentation and filament-associated genes in its pathogenicity
requires further study.
Adherence and Biofilm Formation
Adherence to host cells is essential to microbial colonization,
persistence, and virulence (Mayer et al., 2013; Tsui et al.,
2016). In addition, microbe-microbe adherence mediates the
formation of microbial communities, or biofilms, which are an
important virulence trait in Candida species that confer enhanced
antimicrobial resistance. The C. auris genome encodes several
orthologs of C. albicans adhesins implicated in biofilm formation
and virulence. Clade II strains of C. auris, which predominantly
cause ear infections, have lost significant sections of subtelomeric
regions that are enriched in putative adhesins, but are conserved
in strains from Clades I, III, and IV (Muñoz et al., 2019).
Frontiers in Genetics | www.frontiersin.org 12 April 2020 | Volume 11 | Article 351
fgene-11-00351 April 9, 2020 Time: 15:56 # 13
Chybowska et al. Nine Things About Candida auris
Perhaps future studies will unravel what role these subtelomeric-
encoded adhesins have in human colonization and virulence.
Recent studies have identified differentially regulated adhesin
expression under physiologically-relevant conditions, including
growth at 37◦C in RPMI medium (Kean et al., 2018; Yue et al.,
2018).
Several GPI-anchored cell wall proteins contribute to
microbe-microbe and microbe-host adherence. ALS4 is a
member of the well-characterized ALS adhesin gene family
in C. albicans (Zhao et al., 2005) and its ortholog is also
differentially expressed during C. auris filamentous growth
(Yue et al., 2018). Other GPI-anchored cell wall genes and
potential adhesins were upregulated during C. auris in vitro
biofilm formation compared to planktonic cells (IFF4, CSA1,
PGA26, PGA52, and HYR3) (Kean et al., 2018). Furthermore,
putative orthologs of ALS3, the C. albicans adhesin and
invasin that induces host cell endocytosis of C. albicans
hyphae (Liu and Filler, 2011), were detected on the C. auris
cell surface by an anti-Als3p antibody (Singh et al., 2019).
In addition, two ALS family orthologs, ALS1 and ALS5,
were expressed in biofilms (Kean et al., 2018). Each adhesin
may play an important role in C. auris biofilm formation,
persistence in hospital environments, and virulence, but
further molecular studies are required to tease apart their
independent contributions.
Several efflux pumps were induced in C. auris biofilms versus
planktonic cells (Kean et al., 2018). ATP-binding cassette (ABC)
transporters SNQ2 and CDR1 and major facilitator superfamily
(MFS) genes YHD3, RDC3, and MDR1 were upregulated between
2- and 4-fold in mature 24 h biofilms compared to planktonic
cells. In line with these observations, efflux pump activity was
elevated in mature biofilms relative to planktonic cells (Kean
et al., 2018). Altogether, these findings suggest that biofilm
formation may promote C. auris multi-drug resistance and
virulence. Therefore, as with C. albicans, clinical measures to
tackle C. auris drug resistance should consider the possibility that
biofilms may harbor more drug-resistant cells and reduce the
bioavailability of therapeutics.
Stress Resistance and Persistence
One of the fascinating traits linked to C. auris’ emergence as a
nosocomial pathogen is its ability to persist on abiotic hospital
surfaces under stringent cleaning protocols (Schelenz et al., 2016;
Welsh et al., 2017). Viable C. auris can be recovered from plastic
surfaces or be detected via esterase activity for up to 2 and 4 weeks
post-contamination, respectively (Welsh et al., 2017). These
findings pose an interesting question: can C. auris form viable
but non-culturable cells that persist in hospital environments?
Although no studies to date have directly addressed this question,
current metabolomic, transcriptomic, and molecular studies hold
clues to C. auris’ stress tolerance and persistence.
C. auris metabolism favors respiration as evidenced by
enrichment in glycolytic and sugar transporter gene expression
during yeast growth (Yue et al., 2018) and TCA cycle protein
enrichment compared to C. albicans (Zamith-Miranda et al.,
2019). Respiratory metabolism enhances ATP production and
can reduce oxidative stress in C. albicans, thus promoting in vivo
fitness and fluconazole resistance (Guo et al., 2017). Furthermore,
C. auris lipid profiles show elevated levels of ergosterol and
structural lipids compared to C. albicans, which may influence
stress and antifungal resistance (Zamith-Miranda et al., 2019).
In addition, iron transport (Kean et al., 2018) and iron
metabolism-associated genes (Yue et al., 2018) were upregulated
in C. auris biofilm and filamentous cells, respectively. The
C. auris genome provides evidence for expansion of siderophore-
based iron transporters compared to C. albicans, further
highlighting the importance of iron acquisition in this pathogen
(Muñoz et al., 2018). Iron is an essential micronutrient that
is depleted via nutritional immunity mechanisms in vivo,
thus upregulation of iron uptake and metabolism-associated
genes may improve C. auris fitness during infection. However,
the contribution of C. auris iron transport gene families to
virulence and drug resistance are currently unknown. Still,
the expansion of the iron transport gene family suggests that
iron deprivation may play an influential role in C. auris’
environmental reservoir.
Recent evidence has demonstrated that the stress-activated
protein kinase Hog1 plays an evolutionarily conserved role in
C. auris stress resistance, cell wall homeostasis, and virulence
(Day et al., 2018). C. auris Hog1 shares 87% identity with
the C. albicans Hog1 sequence. Consistent with findings
from other Candida species, C. auris HOG1 was required
for osmotic stress resistance and SDS protection. However,
C. auris HOG1 was not required for weak acid or nitrosative
stress tolerance, which contrasts its role in C. glabrata and
C. albicans, respectively (Day et al., 2018). However, we do
not know which C. auris genes are regulated in a Hog1-
dependent manner or which Hog1 targets are responsible for
these stress-adaptive phenotypes. Future transcriptomics and
molecular studies will hopefully reveal which C. auris stress
response genes are regulated via Hog1, which will highlight the
evolutionary diversification of stress response circuitry across
Candida species.
EPIGENETICS AND GENE REGULATION
IN C. auris
Phenotypic plasticity is the interaction between a given
genotype and the environment to produce multiple phenotypes.
This plasticity is often the result of alterations in gene
expression, which can be influenced by genetic or epigenetic
mechanisms. In pathogens, phenotypic plasticity is often viewed
as system for evolutionary bet-hedging to ensure microbial
survival under shifting and/or hostile environmental conditions
(Carja and Plotkin, 2017).
In the case of C. auris, very little is known about epigenetics
and gene regulation or how these contribute to pathogenesis.
As with other biological and virulence traits, early insights
into C. auris epigenetics have been informed by previous
work in C. albicans. Chromatin modification, including histone
acetylation and deacetylation, plays an important role in
C. albicans virulence (Garnaud et al., 2016; Kuchler et al.,
2016). C. auris histone proteins and modifying enzymes were
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differentially expressed during filamentous growth relative to
yeast, suggesting that epigenetic mechanisms may influence
gene expression patterns in yeast and FC cells (Yue et al.,
2018). In fact, the observation that in vivo passage can trigger
a heritable, filamentation-competent phenotype is suggestive
of epigenetic regulation, but more investigation is required
to understand the mechanisms underlying this trait and its
role in virulence.
Currently, available data demonstrates that C. auris has
significant similarities in gene expression for important
established virulence mechanisms in C. albicans, but there
are also significant differences (Kean et al., 2018; Yue et al.,
2018). Phenotypic heterogeneity between different C. auris
clades provides an opportunity to understand how genetic
mechanisms contribute to pathogenesis (via for example gene
knock out or mutagenesis studies). Indeed, the adaptation
of C. albicans gene deletion technologies for use in C. auris
will enable future molecular investigations to understand gene
regulatory networks and virulence in this emerging pathogen.
Consequently, the C. albicans NAT1-Clox system has been
successfully employed to disrupt C. auris HOG1 and demonstrate
its conserved role in stress responses (Shahana et al., 2014; Day
et al., 2018). Future pathfinding molecular studies should reveal
the conservation and divergence of gene regulatory networks
in C. albicans and C. auris and highlight new avenues for
antifungal development.
SUMMARY
Genomics and other omics studies have provided significant
insight into the biology and pathogenesis of C. auris since
its emergence as a modern human fungal pathogen. However,
several questions remain about the evolution and fitness of this
multi-drug resistant yeast which require further study.
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